The aim of this study was the evaluation of S100B prognostic role in nonmetastatic breast cancer patients, excluding confounding factors. Patients & method: 79 breast cancer patients, who fulfilled inclusion and exclusion criteria, were enrolled in the study. Before any adjuvant chemotherapy or surgery, the serum level of S100B was determined. All patients were followed up for 5 years, particularly regarding cancer recurrence and patients' survival. Results: 42% of the patients experienced no recurrence after 5 years and cumulative risk of recurrence was 0.86. There was no significant correlation between serum level of protein S100B and recurrence rate in 5 years (p = 0.59). Conclusion: According to the results, the serum levels of S100B protein may have no prognostic role in nonmetastatic breast cancer.

No abstract

Aim: 8-OxodG protein has been introduced recently as a new biomarker for breast cancer, according to its role in tumor progression and invasion. In this study, we investigated prognostic value of 8-Oxo-2′-deoxyguanosine (8-OxodG) protein in nonmetastatic breast cancer patients excluding confounding factor. Materials & methods: Before any adjuvant chemotherapy or surgery, serum level of 8-OxodG protein was determined in 79 patients with nonmetastatic breast cancer. All patients follow up for 5 years regarding cancer recurrence and survival. Results: Cumulative risk of recurrence 5 years after the beginning of the study was 0.86 and there was no significant correlation between 8-OxodG and the recurrence rate (p = 0.78). Conclusion: The serum levels of 8-OxodG protein may not be an appropriate prognostic factor in breast cancer.